Grigor'eva N Iu, Kuznetsov A N, Koroleva T V, Koroleva M E
Ter Arkh. 2013;85(8):91-4.
To evaluate the clinical efficacy of the combined drug ascoril (Glenmark, India) in patients with grade I-Ii chronic obstructive pulmonary disease (COPD) concurrent with coronary heart disease (CHD).
Sixty patients, including 12 (20%) women and 48 (80%) men, aged 43 to 68 years (mean age 55.1 +9.9 years), with COPD were examined. The patients were divided into 2 groups. Group 1 used the combined broncholytic and expectorant drug ascoril and Group 2 took mucolytic agent ambroxol. The follow-up period was 7 days.
On day 2 of ascoril treatment, all the patients showed a significant reduction in the intensity of cough that was completely relieved in 26 (87%) patients by treatment day 7. Prior to ascoril treatment, heart rate (HR) was 64.4+/-5.5 beats/min. A significant increase in HR to 72.7+/-10.1 beats/min was observed 20 min after the first drug intake (p < 0.05) and a decrease to 68.6+/-10.5 beats/min was seen after 60 min. On treatment day 7, HR was 63.0+/-6.5 beats/min, which was similar to that before ascoril treatment (p = 0.6).
In the patients with COPD concurrent with CHD, the combined drug ascoril exerts broncholytic and expectorant effects, with no pronounced negative action on HR.
评估复方药物阿斯美（印度格兰马克制药公司生产）对Ⅰ-Ⅱ级慢性阻塞性肺疾病（COPD）合并冠心病（CHD）患者的临床疗效。
对60例慢性阻塞性肺疾病患者进行检查，其中女性12例（20%），男性48例（80%），年龄43至68岁（平均年龄55.1±9.9岁）。患者被分为两组。第1组使用复方支气管扩张祛痰药阿斯美，第2组服用黏液溶解剂氨溴索。随访期为7天。
在阿斯美治疗第2天，所有患者咳嗽强度均显著降低，至治疗第7天，26例（87%）患者咳嗽完全缓解。在服用阿斯美前，心率（HR）为64.4±5.5次/分钟。首次服药20分钟后，心率显著升至72.7±10.1次/分钟（p<0.05），60分钟后降至68.6±10.5次/分钟。在治疗第7天，心率为63.0±6.5次/分钟，与服用阿斯美前相似（p=0.6）。
对于慢性阻塞性肺疾病合并冠心病患者，复方药物阿斯美具有支气管扩张和祛痰作用，对心率无明显不良影响。
